Background: Drug-eluting stents with durable biocompatible or biodegradable polymers have been developed to address the risk of thrombosis associated with first-generation drug-eluting stents. We aimed to compare the safety and efficacy of a biodegradable polymer-coated biolimus-eluting stent with a thin-strut everolimus-eluting stent coated with a durable biocompatible polymer.
Background: Third-generation biodegradable polymer drug-eluting stents might reduce the risk of stent thrombosis compared with first-generation permanent polymer drug-eluting stents. We aimed to further investigate the effects of a biodegradable polymer biolimus-eluting stent compared with a durable polymer-coated sirolimus-eluting stent in a population-based setting.
Background: Patients with diabetes mellitus (DM) undergoing percutaneous cardiovascular intervention (PCI) represent a challenging population with higher risk of adverse events compared to non-diabetic patients. We investigated the impact of DM on long-term clinical outcomes of biolimus-eluting stents (BES) with biodegradable polymer versus sirolimus-eluting stents (SES) with durable polymer within the randomized multi-center all-comers LEADERS trial through 5 years.
Background: The aim of this study is to compare the safety, efficacy and durability of Sirolimus (SES), Paclitaxel (PES), Zotarolimus (ZES-R/ Endeavor Resolute), BiolimusA9 (BES), EPC capture (ECS) and Everolimus-eluting stent (EES) on the outcome of patients with left main coronary arteries (LMT) stenosis
Background: Second-generation drug eluting stents (DES) have shown a high efficacy in terms of restenosis prevention, like first-generation DES, with reduced rates of stent thrombosis, especially late stent thrombosis. The suggested mechanism for this superiority is a better morphological and functional healing response. The objective of this study is to compare the efficacy and safety results of 2 different, first and second-generation, DES in a swine model of normal coronary arteries
Background: Patients with diabetes show higher rates of restenosis and stent thrombosis following PCI. Optimal for treatment of patients with diabetes is not known and no stent has demonstrated superior efficacy or safety. Late stent thrombosis is associated with impaired endothelial coverage and adverse vessel remodeling- both features of delayed arterial healing caused by permanent polymer drug-eluting stents (DES). Biodegradable polymer DES offer improved biocompatibility and may improved long-term outcomes.
Background: The aim of this study is to compare the safety and efficacy of Sirolimus (SES), Paclitaxel (PES), Zotarolimus (ZES-R/ Endeavor Resolute), BiolimusA9 (BES), EPC capture (ECS) and Everolimus-eluting stent (EES) on the outcome of stenting in patients with diabetic very long coronary lesion (VLL) (lesion length ≥40 mm).
Background: The aim of this study is to compare the safety and efficacy of Sirolimus (SES), Paclitaxel (PES), Zotarolimus (ZES-R/ Endeavor Resolute), BiolimusA9 (BES), EPC capture (ECS) and Everolimus-eluting stent (EES) on the outcome of treatment of small coronary artery disease with diabetes mellitus (DM).
Background: Diabetes is associated with an increased risk of major adverse cardiac events (MACE) following percutaneous coronary intervention.
Background: Neointimal growth patterns of new generation drug-eluting stents are not yet fully elucidated. We developed a new visualization method and compared neointimal growth patterns between biodegradable polymer biolimus-eluting stent (BES) and permanent polymer everolimus-eluting stent (EES) using optical coherence tomography (OCT).
Background: Biodegradable polymer drug eluting stents improve safety and efficacy when compared to durable polymer drug eluting stents, but this may not be true in diabetic patients.
Background: Nobori stent (Terumo Co., Tokyo Japan), is the new concept Drug Eluting Stent which has unique bioabsorbable polymer (Poly-Lactic Acid) and the anti-proliferative agent Biolimus A9. We investigated the safety and the efficacy of Nobori stent comparing to Cypher stent in Japanese population by a single blinded 3:2 randomized trial and met the primary endpoint, non inferiority in TVF. This is the first report of three year clinical follow up data of Nobori Biolimus Eluting stent compared to Cypher Sirolimus Eluting stent in Japanese population.
Background: With the introduction of drug eluting stents (DES) in this decade, treatment of patients with STEMI with these devices has emerged as a rational PCI alternative. In spite of the unquestionable benefits of DES in terms of reduction of restenosis and TVR, specific concerns have arisen with regard to their short- and long-term safety. We aim to assess short- and long-term outcomes in STEMI patients treated with Nobori, DES with biodegradable polymer.